Compound

Company

Structure

Stage of development

Mechanism of action

Targeting the androgen pathway

Abiraterone

Janssen

Oral androgen biosynthesis inhibitor

Phase III

17 a-hydroxylase/C17,20-lyase (CYP17) inhibitor

Enzalutamide

Astellas

Oral hormonal therapy

Phase III

Androgen receptor antagonist

Orteronel

Takeda Pharmaceutical Company

Oral androgen biosynthesis inhibitor

Phase III

CYP17A1 inhibitor

Galeterone

Tokai Pharmaceuticals

Oral hormonal therapy and androgen biosynthesis inhibitor

Phase III

Both androgen receptor antagonist and an CYP17A1 inhibitor

ARN-509

Johnson & Johnson

Oral hormonal therapy

Phase III

Androgen receptor antagonist

ODM-201

Orion and Bayer Health Care

Oral hormonal therapy

Phase III

Androgen receptor antagonist

Targeting bone microenvironment

Zoledronic Acid

Novartis

Intravenous bone resorption inhibitor

Phase IV

Farnesyl pyrophosphate sy50*ntetase inhibitor

Denosumab

Amgen

Subcoutaneus bone resorption inhibitor

Phase IV

RANK-L antibody

Radium-223

Bayer

Isotope of radium

Phase III

Radiopharmaceutical

alpha-particles target

Targeting signal transduction pathways

Cabozantinib

Exelixis

Oral small molecule TKi

Phase III

c-MET/HGF pathway inhibitor

Dasatinib

Bristol-Myers Squibb

Oral small molecule TKi

Phase III

c-Src/Abl kinase inhibitor

Zibotentan

AstraZeneca

Oral small molecule

Phase III

Endothelin receptor A antagonist

Immunotherapies

Sipuleucel-T

Dendreon Corporation

Intravenous autologous cellular immunotherapy

Phase III

Immunomodulatory agent

Ipilimumab

Bristol-Myers Squibb

Intravenous monoclonal antibody

Phase III

CTLA-4 inhibitor and immunomodulatory agent

Other molecules

Tasquinimod

Ipsen and Active Biotech

Oral small molecule tumor microenvironment inhibitor

Phase III

S100A9 inhibitor

Custirsen

Oncogenex Pharma

Intravenous antiapoptotic signalling inhibitor

Phase III

Clusterin production inhibitor